


Examining an evolving treatment landscape

CONTEXTUALIZING THE ROLE OF IMMUNOTHERAPY AS A FIRST LINE OPTION IN THORACIC CANCER

This presentation has been previously recorded in October 2020. The virtual session presented live was approved by the Canadian Association of Medical Oncologists (CAMO) as an Accredited Group Learning Activity (Section 1 credit), as defined by the Maintenance of Certification program of the Royal College of Physicians and Surgeons of Canada, for a maximum of 1 hour.

After viewing and listening the recorded format of this learning activity, you will find the steps to claim Self-learning (Section 2) credits.

WEBINAR



WITH
Dr. Hossein Borghaei, MS, DO

Professor of Medical Oncology,
Chief of Thoracic Medical Oncology,
Director of the lung/ head and neck
cancer risk assessment program at Fox
Chase Cancer Center in Philadelphia,
Pennsylvania.

MODERATOR

Dr. Catherine Labbé

Pulmonologist, Laval University Institute
of Cardiology and Pneumology of Quebec
Quebec, QC

LEARNING OBJECTIVES

- 1 Discuss the evolving landscape for the 1st line management of Non-small cell lung cancer (NSCLC)
- 2 Integrate the latest evidence regarding the efficacy of immunotherapy-based therapies for the treatment of NSCLC into clinical practice
- 3 Recall the most recent clinical evidence for the 1st line management of malignant pleural mesothelioma

To view this presentation

CLICK HERE

OR

Type <https://iothoracic.ca>
in the address bar
of your Internet browser.

Access code:
IOTHORACIC_OCT20